2011, FDA and Pharmacology - Pharma Rep Focus

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2011

FDA

Pharmacology

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

SEPTEMBER 22, 2023

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.

Food and Drug Administration

Food and Drug Administration Safety Patients Leads

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

JULY 4, 2024

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few? 3 Is two too few?

Marketing

Marketing Food and Drug Administration Medicine Prescription

Webinars

The Intersection of AI and Sales: Personalization Without Compromise

MORE WEBINARS

Paving the way for anti-Abeta active immunotherapy

Botanical drugs – what is the best way forward for regulatory and market approval?

Webinars

Stay Connected